This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

RD Legal Funding Offers Post-Settlement Advances As Johnson & Johnson Makes Settlement Offer To DePuy Litigants Following FDA Warning

However the recent FDA proposal does not address all the concerns with the devices. DePuy identified reasons for the failure of the hip replacement as component loosening, misalignment, infection, bone fracture, dislocation, metal sensitivity, and pain. Problems with the devices go beyond the risks of replacement surgeries. Additional complications may include:

  • Residual - possibly deadly - metal fragments going undetected for years;
  • Increased metal ion levels in the blood;
  • Bone staining;
  • Swelling;
  • Nerve, tissue and/or muscle damage or necrosis;
  • Damage to the central nervous system including thyroid and heart;
  • Poisoning of major organs causing genetic changes and increasing cancer risks, particularly to the kidneys and bladder.

Another factor in J & J's willingness to settle the suits may be their agreement, in September 2007, along with three other companies to pay $311 million in fines - without admitting any wrongdoing - to resolve U.S. Department of Justice allegations that they paid physicians kickbacks to use their artificial hip and knee products. The settlement agreement allowed the companies to continue to enter into product development agreements with doctors, compensating them with royalties based on future sales. DePuy paid nearly $48 million to doctors in 2009 and almost $33 million in the first 9 months of 2010.

For more information about post-settlement financing, DePuy litigants and their attorneys should contact RD Legal Funding at 1-800-565-5177 or go to legalfunding.com. Founded in 1997, RD Legal Funding is now one of the nation's leading providers of post-settlement lawsuit funding to attorneys and plaintiffs.

SOURCES:

http://www.reuters.com/article/2013/01/17/us-fda-hips-idUSBRE90G0W520130117

http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/MetalonMetalHipImplants/default.htm

http://www.prweb.com/releases/rottenstein-law-group/wright-hip-lawsuit/prweb10338691.htm

http://www.reuters.com/article/2013/01/18/us-jj-hips-idUSBRE90H18E20130118

http://www.bloomberg.com/news/2013-01-18/j-j-said-to-offer-implant-pact-that-may-reach-2-billion.html

SOURCE RD Legal Funding

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,719.00 +33.27 0.19%
S&P 500 2,052.75 +4.03 0.20%
NASDAQ 4,701.8670 +26.1550 0.56%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs